OT3-01-15: Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer: The LEA Study.
la Haba-Rodriguez JR De, Minckwitz G von, M Martín, S Morales, C Crespo, A Guerrero, A Anton-Torres, M Gil, M Muñoz, E Carrasco, C Rodríguez-Martin, I Porras, B Aktas, W Schoenegg, J Tio, K Mehta, S Loibl, Behalf of GEICAM and GBG On
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 September 2024.
All research outputs
#5,167,900
of 26,690,210 outputs
Outputs from Cancer Research
#4,726
of 19,393 outputs
Outputs of similar age
#38,788
of 254,492 outputs
Outputs of similar age from Cancer Research
#31
of 159 outputs
Altmetric has tracked 26,690,210 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 19,393 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 254,492 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 159 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.
